Charles River Laboratories International (NYSE:CRL) Stock Gets Downgrade from Zacks Research

Charles River Laboratories International (NYSE:CRL) was downgraded by research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued on Monday, Zacks reports.

CRL has been the topic of a number of other reports. Robert W. Baird upped their price target on shares of Charles River Laboratories International from $291.00 to $334.00 and gave the stock an “outperform” rating in a report on Friday, September 25th. Piper Sandler set a $300.00 price objective on shares of Charles River Laboratories International in a report on Monday, August 10th. Jefferies Financial Group boosted their price objective on shares of Charles River Laboratories International from $305.00 to $340.00 and gave the company a “buy” rating in a research report on Monday, September 28th. CLSA lowered shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 target price on the stock. in a research report on Monday, July 20th. Finally, TD Cowen boosted their price target on Charles River Laboratories International from $300.00 to $325.00 and gave the company a “buy” rating in a report on Friday, September 25th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $302.33.

Charles River Laboratories International Stock Up 3.5%

Shares of NYSE:CRL opened at $350.30 on Monday. Charles River Laboratories International has a 1 year low of $146.20 and a 1 year high of $379.63. The business has a 50 day simple moving average of $303.97 and a two-hundred day simple moving average of $223.61. The firm has a market capitalization of $16.72 billion, a PE ratio of -72.23, a price-to-earnings-growth ratio of 3.16 and a beta of 1.36. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, November 4th. The medical research company reported $3.09 EPS for the quarter, beating the consensus estimate of $2.97 by $0.12. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%. The company had revenue of $982.73 million for the quarter, compared to the consensus estimate of $960.36 million. On average, equities analysts predict that Charles River Laboratories International will post 11.38 EPS for the current year.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, Director James C. Foster sold 24,042 shares of Charles River Laboratories International stock in a transaction dated Thursday, October 22nd. The stock was sold at an average price of $350.00, for a total value of $8,414,700.00. Following the transaction, the director owned 31,596 shares in the company, valued at $11,058,600. The trade was a 43.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy C. Andrews sold 573 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $285.24, for a total value of $163,442.52. Following the sale, the director owned 1,438 shares of the company’s stock, valued at approximately $410,175.12. This represents a 28.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 113,123 shares of company stock valued at $33,864,118 over the last 90 days. Company insiders own 1.30% of the company’s stock.

Institutional Trading of Charles River Laboratories International

Several large investors have recently bought and sold shares of CRL. North Dakota State Investment Board increased its holdings in Charles River Laboratories International by 2.7% in the third quarter. North Dakota State Investment Board now owns 1,489 shares of the medical research company’s stock valued at $439,000 after buying an additional 39 shares in the last quarter. Physician Wealth Advisors Inc. lifted its stake in shares of Charles River Laboratories International by 127.9% in the third quarter. Physician Wealth Advisors Inc. now owns 98 shares of the medical research company’s stock worth $29,000 after buying an additional 55 shares in the last quarter. Activest Wealth Management boosted its position in Charles River Laboratories International by 25.9% during the third quarter. Activest Wealth Management now owns 277 shares of the medical research company’s stock worth $82,000 after acquiring an additional 57 shares during the last quarter. Choreo LLC boosted its position in Charles River Laboratories International by 2.8% during the third quarter. Choreo LLC now owns 2,165 shares of the medical research company’s stock worth $639,000 after acquiring an additional 59 shares during the last quarter. Finally, Empirical Finance LLC boosted its position in Charles River Laboratories International by 4.4% during the second quarter. Empirical Finance LLC now owns 1,469 shares of the medical research company’s stock worth $333,000 after acquiring an additional 62 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.